Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Catalyst Pharmaceuticals(CPRX) Newsfilter·2024-02-21 14:00CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced that the peer-reviewed journal Neurology has published Santhera Pharmaceutical's ("Santhera") study titled "Efficacy and Safety of Vamorolone Over 48 Weeks in ...